屋尘螨免疫治疗对单一致敏与多重致敏过敏性鼻炎患者的临床疗效:系统评价与Meta分析
该系统评价与Meta分析纳入9项研究,比较屋尘螨过敏原特异性免疫治疗在单一致敏与多重致敏过敏性鼻炎患者中的临床疗效。主要结局鼻症状评分的变化在两组间无显著差异,次要结局用药评分与生活质量评分亦无显著差异。结论认为,采用屋尘螨提取物的单一致敏原免疫治疗在多重致敏与单一致敏过敏性鼻炎患者中显示出相当的临床疗效。
要点
- 屋尘螨AIT后鼻症状评分改善在单一致敏与多重致敏AR患者间无显著差异
- 用药评分与生活质量评分的改善在两组间同样无显著差异
- 多重致敏AR患者可考虑使用屋尘螨单一致敏原AIT,疗效与单一致敏者相当
核心结论
- 采用屋尘螨提取物的单一致敏原AIT在多重致敏与单一致敏过敏性鼻炎患者中显示出相当的临床疗效。
研究设计与样本
- 系统评价与Meta分析,共分析9项研究,比较屋尘螨AIT在单一致敏与多重致敏过敏性鼻炎患者中的临床疗效。
主要发现
- 主要结局鼻症状评分在屋尘螨AIT后的变化,在单一致敏与多重致敏患者间无显著差异。
- 次要结局用药评分与生活质量评分方面,屋尘螨AIT的临床疗效在单一致敏与多重致敏患者间无显著差异。
临床怎么用
- 为多重致敏过敏性鼻炎患者选择AIT方案时,屋尘螨单一致敏原AIT可作为与单一致敏患者相当的选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Selecting an appropriate allergen-specific immunotherapy (AIT) regimen for polysensitised allergic rhinitis (AR) patients is challenging for clinicians. Although previous studies showed comparable effectiveness of single-allergen AIT with house dust mite (HDM) extract between monosensitised and polysensitised AR patients, there is no systematic review and meta-analysis demonstrating the comparable effectiveness of HDM AIT. In this meta-analysis, we analysed nine studies to compare the clinical effectiveness of HDM AIT. The primary outcome was nasal symptom score and secondary outcomes were medication and quality of life scores. The changes in nasal symptom score after HDM AIT did not significantly differ between monosensitised and polysensitised patients. The clinical effectiveness of HDM AIT regarding medication and quality of life score was not significantly different between monosensitised and polysensitised patients). In conclusion, single-allergen AIT with HDM extract showed comparable clinical effectiveness between polysensitised and monosensitised patients with AR.
引用
- Kim JY, Hwang D, Jang M, et al. Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2021. PMID: 34180463. doi:10.4193/Rhin20.588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。